TetraLogic Pharmaceuticals Corp Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and TetraLogic Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days TetraLogic Pharmaceuticals Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, TetraLogic Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 13.1 M | |
| Total Cashflows From Investing Activities | 35.4 M |
TetraLogic |
TetraLogic Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest (100.00) in TetraLogic Pharmaceuticals Corp on December 27, 2024 and sell it today you would earn a total of 100.00 from holding TetraLogic Pharmaceuticals Corp or generate -100.0% return on investment over 90 days. TetraLogic Pharmaceuticals Corp is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than TetraLogic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TetraLogic Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TetraLogic Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as TetraLogic Pharmaceuticals Corp, and traders can use it to determine the average amount a TetraLogic Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| TLOG |
Based on monthly moving average TetraLogic Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TetraLogic Pharmaceuticals by adding TetraLogic Pharmaceuticals to a well-diversified portfolio.
TetraLogic Pharmaceuticals Fundamentals Growth
TetraLogic Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of TetraLogic Pharmaceuticals, and TetraLogic Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TetraLogic Pink Sheet performance.
| Return On Asset | -0.2 | ||||
| Current Valuation | 458.72 K | ||||
| Shares Outstanding | 24.47 M | ||||
| Price To Earning | (0.03) X | ||||
| Price To Book | 0.40 X | ||||
| EBITDA | (43.15 M) | ||||
| Cash And Equivalents | 5.89 M | ||||
| Cash Per Share | 0.24 X | ||||
| Total Debt | 28.33 M | ||||
| Debt To Equity | 4.17 % | ||||
| Book Value Per Share | (1.25) X | ||||
| Cash Flow From Operations | (34.89 M) | ||||
| Earnings Per Share | (1.65) X | ||||
| Total Asset | 64.02 M | ||||
| Retained Earnings | (175.56 M) | ||||
| Current Asset | 21.97 M | ||||
| Current Liabilities | 3.66 M | ||||
Things to note about TetraLogic Pharmaceuticals performance evaluation
Checking the ongoing alerts about TetraLogic Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for TetraLogic Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TetraLogic Pharmaceuticals is not yet fully synchronised with the market data | |
| TetraLogic Pharmaceuticals has some characteristics of a very speculative penny stock | |
| TetraLogic Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| TetraLogic Pharmaceuticals Corp currently holds 28.33 M in liabilities with Debt to Equity (D/E) ratio of 4.17, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. TetraLogic Pharmaceuticals has a current ratio of 0.47, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist TetraLogic Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, TetraLogic Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like TetraLogic Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for TetraLogic to invest in growth at high rates of return. When we think about TetraLogic Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (49.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| TetraLogic Pharmaceuticals Corp currently holds about 5.89 M in cash with (34.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24. |
- Analyzing TetraLogic Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TetraLogic Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining TetraLogic Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TetraLogic Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of TetraLogic Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TetraLogic Pharmaceuticals' pink sheet. These opinions can provide insight into TetraLogic Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in TetraLogic Pink Sheet
If you are still planning to invest in TetraLogic Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TetraLogic Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |